loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Cipla has received USFDA approval for its ANDA for Generic Advair Diskus in all three strengths

ICICIdirect Research 28 Jul 2026 DISCLAIMER

News: Cipla has received USFDA approval for its ANDA for Generic Advair Diskus in all three strengths. The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD) and has estimated market of ~US$908 million (IQVIA).  

View: The approval of Generic Advair represents a significant milestone for Cipla's FY27 US respiratory pipeline, which includes Advair, Symbicort, and Qvar. Our estimates had already factored in Generic Advair's contribution starting from H1FY27, making the approval consistent with our expectations.   

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere